AstraZeneca medicine achieves important milestone

AstraZeneca’s BRILINTA® (ticagrelor) tablets have marked an important milestone today with its addition to key Clinical Practice Guidelines.

In the months since FDA approval, BRILINTA has continued to demonstrate its value as an important medicine for appropriate patients and this recommendation further underscores BRILINTA as a valuable treatment option for patients.

Please read Medication Guide and full Prescribing Information, including Boxed WARNINGS, for BRILINTA.

To read more about this news, click here.

By Stephanie Jacobson, Director, Brand Corporate Affairs at AstraZeneca